Health Condition 1: K769- Liver disease, unspecified
Conditions
Interventions
Intervention1: Carvedilol at Day2 with Standard Medical
Treatment: Arm A- Carvedilol will be initiated on day 2, at a dose
of 3.125mg twice a day (6.25mg/day), along with
standard management as per in
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Cirrhosis with Acute Variceal Bleed 2. Childâ??s B and C cirrhosis (CTP 3. Patients age between 18 to 75 years
Exclusion criteria
Exclusion criteria: 1. Gastric variceal bleed 2. Bleeding related to coagulopathy 3. Other causes of portal hypertensive bleeding. 4. Acute on chronic liver failure 5. Sepsis 6. Shock(persistence of hypotension) 7. Acute kidney injury ( >1.5 mg%) 8. Grade 3 Ascites 9. Hyponatremia (Na 10. Complete portal vein thrombosis 11. Hepatocellular carcinoma ( >3cm lesion) 12. Tumoral portal vein thrombosis 13. Chronic kidney disease 14. Coronary artery disease 15. Valvular heart disease 16. Sick sinus syndrome/ Pacemaker 17. Arrythmia 18. Uncontrolled hypothyroidism and hyperthyroidism. 19. Pregnancy 20. Failure to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hemodynamic response in both groupsTimepoint: Day 5 | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Effects in both groupsTimepoint: 6 weeks;Death in both groupsTimepoint: 6 weeks;Decompensation events at 6-weeks in both groupsTimepoint: 6 weeks;Rebleeding within 6-week in both groupsTimepoint: 6 weeks | — |
Countries
India
Contacts
Public ContactDr V Rajan
Institute of Liver and Biliary Sciences
Outcome results
None listed